Contineum Therapeutics Inc. has described lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of cancer, idiopathic pulmonary fibrosis, renal fibrosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH) and scleroderma.